With this notice, Frontiers states its awareness of the serious concerns raised regarding this article, which are now under investigation. The situation will be updated as soon as the investigation is complete.
Summary
Keywords
microbiome, COVID, SARS – CoV – 2, bifidobacetrium, TNF-a (tumor necrosis factor a), Ivermectin
Citation
Frontiers Editorial Office (2023) Expression of concern: Microbiome-based hypothesis on Ivermectin's mechanism in COVID-19: Ivermectin feeds bifidobacteria to boost immunity. Front. Microbiol. 13:1128469. doi: 10.3389/fmicb.2022.1128469
Received
20 December 2022
Accepted
20 December 2022
Published
05 January 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2023 Frontiers Editorial Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Editorial Office ✉ editorial.office@frontiersin.org
This article was submitted to Infectious Agents and Disease, a section of the journal Frontiers in Microbiology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.